We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+32.17%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.01B
AUM Growth
+$300M
Cap. Flow
-$394M
Cap. Flow %
-7.86%
Top 10 Hldgs %
36.48%
Holding
142
New
15
Increased
17
Reduced
27
Closed
32

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$105M
2
BIIB icon
Biogen
BIIB
+$66.5M
3
ELV icon
Elevance Health
ELV
+$65.4M
4
SRRK icon
Scholar Rock
SRRK
+$27.5M
5
ARGX icon
argenx
ARGX
+$24.2M

Top Sells

Rank Stock Value
1
HUM icon
Humana
HUM
+$115M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$85.3M
3
BAX icon
Baxter International
BAX
+$84.5M
4
CI icon
Cigna
CI
+$66.2M
5
ABBV icon
AbbVie
ABBV
+$49.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.96%
2 Industrials 1.01%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVA
1
DELISTED
Sinovac Biotech, Ltd
SVA
$340M 6.79%
2,718,735
– –
BIIB icon
2
Biogen
BIIB
$30.4B
$214M 4.28%
827,600
+270,800
+49% +$66.5M
LLY icon
3
Eli Lilly
LLY
$1.09T
$213M 4.25%
365,400
+179,400
+96% +$105M
BSX icon
4
Boston Scientific
BSX
$68.5B
$191M 3.82%
3,306,800
– –
ISRG icon
5
Intuitive Surgical
ISRG
$130B
$168M 3.36%
499,000
– –
EWTX icon
6
Edgewise Therapeutics
EWTX
$4.34B
$159M 3.18%
14,567,176
– –
BMRN icon
7
BioMarin Pharmaceuticals
BMRN
$12B
$152M 3.03%
1,571,410
-43,800
-3% -$3.87M
RYZB
8
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$147M 2.94%
2,365,213
-257,696
-10% -$6.41M
ELVN icon
9
Enliven Therapeutics
ELVN
$3.84B
$125M 2.49%
8,998,338
– –
SWTX
10
DELISTED
SpringWorks Therapeutics
SWTX
$118M 2.35%
3,219,359
-749,229
-19% -$19.6M
MRK icon
11
Merck
MRK
$326B
$115M 2.3%
1,055,000
– –
IONS icon
12
Ionis Pharmaceuticals
IONS
$9.14B
$104M 2.09%
2,064,797
-104,703
-5% -$5.02M
IRON icon
13
Disc Medicine
IRON
$2.85B
$98.3M 1.96%
1,702,237
-567,400
-25% -$29.1M
GRCL
14
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$93.5M 1.87%
9,308,726
– –
THC icon
15
Tenet Healthcare
THC
$22.6B
$92.5M 1.85%
1,224,400
– –
EVH icon
16
Evolent Health
EVH
$421M
$90.7M 1.81%
2,746,532
-149,100
-5% -$4.22M
UTHR icon
17
United Therapeutics
UTHR
$26.1B
$84.9M 1.7%
386,100
-15,800
-4% -$3.64M
XTNT icon
18
Xtant Medical Holdings
XTNT
$59.7M
$82.6M 1.65%
73,114,592
– –
SYK icon
19
Stryker
SYK
$133B
$80.6M 1.61%
269,000
– –
SRRK icon
20
Scholar Rock
SRRK
$5.92B
$79.8M 1.59%
4,245,000
+2,211,211
+109% +$27.5M
TMO icon
21
Thermo Fisher Scientific
TMO
$214B
$76.3M 1.52%
143,800
– –
VRNA
22
DELISTED
Verona Pharma
VRNA
$75.1M 1.5%
3,777,778
– –
PCVX icon
23
Vaxcyte
PCVX
$7.88B
$72.4M 1.45%
1,153,091
+145,943
+14% +$7.58M
THRX
24
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$71.7M 1.43%
17,713,600
– –
VRTX icon
25
Vertex Pharmaceuticals
VRTX
$124B
$71.3M 1.42%
175,200
+9,800
+6% +$3.62M
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2023 Portfolio in Review

As of Q4 2023, OrbiMed held 142 positions worth $5.01B, up 6.4% from $4.71B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

OrbiMed withdrew a net $394M in Q4 2023, closing 32 positions and reducing 27 holdings. Its most notable exit was Mirati Therapeutics, Inc. Common Stock, an estimated $85.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, OrbiMed opened a new position in Elevance Health worth $66.7M.

  • OrbiMed's largest Q4 2023 buy was Elevance Health: 141,500 shares worth $66.7M.
  • OrbiMed added most to Eli Lilly in Q4 2023, an estimated $105M increase.
  • OrbiMed's biggest Q4 2023 reduction was Humana, cutting an estimated $115M.
  • OrbiMed fully exited Mirati Therapeutics, Inc. Common Stock in Q4 2023, selling an estimated $85.3M.
  • OrbiMed's ten largest holdings make up 36% of its $5.01B portfolio in Q4 2023.
  • OrbiMed opened 15 new positions and closed 32 in Q4 2023.
  • OrbiMed's portfolio value rose 6.4% quarter-over-quarter to $5.01B.

Based on OrbiMed's 13F filing for Q4 2023, filed 14 Feb 2024.